Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-19T03:49:32.946Z Has data issue: false hasContentIssue false
  • English
  • Français

PREVENTION COULD BE LESS COST-EFFECTIVE THAN CURE: THE CASE OF HEPATITIS C SCREENING POLICIES IN FRANCE

Published online by Cambridge University Press:  21 April 2004

Sandrine Loubière ,
Michel Rotily  and
Jean-Paul Moatti
Sandrine Loubière
Affiliation:
INSERM, U379
Michel Rotily
Affiliation:
INSERM, U379
Jean-Paul Moatti
Affiliation:
INSERM, U379
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: To access the cost-effectiveness of French recommendations for hepatitis C virus (HCV) screening and the extent to which earlier identification of carriers may or not improve the cost-effectiveness of therapeutic strategies.

Methods: Cost-effectiveness analysis were performed using decision-tree analysis and a Markov model. Four alternative strategies were compared: no screening and no treatment; initiation of HCV treatment after the diagnosis of cirrhosis; and two alternative strategies refer to the current French policies of HCV testing, i.e., two enzyme immunoblot assay (EIA) tests in series, or a polymerase chain reaction (PCR) analysis after the first positive EIA test. Costs were computed from the viewpoint of the health care system. The analysis has been applied to populations particularly at risk of infection, as well as the general population.

Results: The “wait and treat cirrhosis” strategy was more cost-effective in the general population and in transfusion recipients. The incremental cost-effectiveness ratio of this strategy compared with baseline strategy was 3,476 of euros and €15,300 in respective cohorts. Considering the HCV screening strategy, the additional cost would be of €4,933 and €240,250 per additional year of life saved, respectively. In the intravenous drug user (IDU) population, the “two EIA” screening strategy was the more cost-effective alternative, with an additional cost of €3,825 per additional year of life saved.

Conclusions: HCV screening would be discarded for transfusion recipients but should be encouraged for IDUs and also for the general population, in which the additional cost of screening is an order of magnitude more acceptable.

Keywords

Cost effectivenessHepatitis CScreeningPreventionMarkov
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 19 , Issue 4 , December 2003 , pp. 632 - 645
Copyright
© 2004 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alter MJ, Kruszon-Moran D, Nainan OV,et al. 1999 The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 34: 556- 562.Google Scholar
ANAES. 1997 Conférence de consensus française. Hépatite C: dépistage et traitement. Virologie. 1: 145- 162.
Aubert C, Colin C. 1998 Dépistage de l'hépatite C avant et après transfusion; Evaluation médico-économique des stratégies de dépistage des hépatites C et non-A, non-B, non-C chez les receveurs de produits sanguins labiles. Lyon (France): Département d'Information Médicale, Hospices Civils de Lyon; sponsored by the Fonds d'Orientation à la Recherche en Transfusion Sanguine (FORTS);
Bello PY, Pasquier C, Gourney P,et al. 1998 Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. Eur J Clin Microbiol Infect Dis. 17: 570- 572.Google Scholar
Bennett W, Inoue Y, Beck R,et al. 1997 Estimates of the cost-effectiveness of a single course of interferon alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 127: 855- 865.Google Scholar
Bennett W, Pauker S, Davis G, Wong J. 1996 Modelling therapeutic benefit in the midst of uncertainty: Therapy for hepatitis C. Dig Dis Sci. 41: 56S- 62S.Google Scholar
Colin C, Lanoir D, Touzet S,et al. 2001 Sensitivity and specificity of third generation hepatitis C virus antibody detection assays: An analysis of the literature. J Viral Hepat. 8: 87- 95.Google Scholar
Craxi A, Di Marco V, Camma C,et al. 1996 Duration of HCV infection as a predictor of nonresponse to interferon. Dig Dis Sci. 41: 86S- 92S.Google Scholar
Davis G, Esteban MR, Rustgi V,et al. 1998 Interferon Alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339: 1493- 1499.Google Scholar
Desenclos J, Dubois F, Couturier E,et al. 1996 Estimation du nombre de sujets infectés par le VHC en France, 1994-95. BEH. 5: 22- 23.Google Scholar
DRASS. 2001 Hépatite C: Programme régional Provence Alpes Côte d'Azur: Un état des lieux en 2000. Marseille: Direction Régionale des Affaires Sanitaires et Sociales; 1- 111.
DRESS. 2001 La prise en charge des toxicomanes dans les structures sanitaires et sociales – nov 1999. Paris: Séries études – documents de travail;
Dubois F, Desenclos J, Mariotte N,et al. 1997 Hepatitis C in a French population based survey, seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology. 25: 1490- 1496.Google Scholar
EASL. 1999 International Consensus Conference on Hepatitis C. Paris, 26-28 février 1999, Consensus statement. J Hepatol. 30: 956- 961.
Fischhoff B, Lichtenstein S, Slovic P,et al. 1981 Acceptable risk. Boston: Cambridge University Press.
Galli M, Musicco M. 1994 Mortality of intravenous drug users living in Milan, Italy: Role of HIV-1 infection. AIDS. 8: 1457- 1463.Google Scholar
Gerken G. 1996 Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol. 24: 33- 37.Google Scholar
Gold M, Siegel J, Russell L,et al. 1996 Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
Grönbladh L, öhlund L, Grunne L. 1990 Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatr Scand. 82: 223- 227.Google Scholar
Hennig H. 2000 Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods. 84: 181- 190.Google Scholar
Hillner B, Smith T, Desh C. 1993 Assessing the cost-effectiveness of adjuvant therapies in breast cancer using decision analysis model. Breast Cancer Res Treat. 25: 97- 105.Google Scholar
Joe G, Simpson D. 1987 Mortality rate among opioid addicts in a longitudinal study. Am J Public Health. 77: 347- 348.Google Scholar
Karlsson G, Johannesson M. 1996 Decision roles of cost-effectiveness analysis. Pharmacoeconomics. 9: 113- 120.Google Scholar
Kenkel D. 2000 Prevention. In: Culyer AJ, Newhouse JP, eds. Handbook of health economics. Amsterdam: Elsevier; 1675- 1719.
Kim W, Poterucha J, Gross J,et al. 1997 Cost-effectiveness of 6 and 12-months of interferon-alpha treatment for chronic hepatitis C. Ann Intern Med. 127: 866- 873.Google Scholar
Koretz R. 1993 Non A Non B post-transfusion hepatitis: Looking back in the second decade. Ann Intern Med. 119: 110- 115.Google Scholar
Kourilsky P, Viney G. 2000 The precaution principle: Report to the Prime Minister. Paris: Odile Jacob Editors;
Laupacis A, Feeny D, Detsky A,et al. 1993 Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 148: 927- 929.Google Scholar
Lavanchy D. 1996 Evaluation of a new automated third-generation anti-HCV enzyme immunoassay. J Clin Lab Anal. 10: 269- 276.Google Scholar
Loubière S, Rotily M, Durand-Zaleski I, Costagliola D. 2001 Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sang. 80: 199- 204.Google Scholar
MacDonald KL, Mills WA, Wood RC,et al. 1994 Evaluation of clinical and laboratory aspects of antibody tests for detection of hepatitis C virus infection in blood donors and recipients from a low-risk population. Transfusion. 34: 202- 208.Google Scholar
Mathoulin-Pelissier S, 1998 for the Centre National d'Hémovigilance. Etude sur les receveurs et produits transfusés en France Métropolitaine (study RECEPT). Bordeaux: Université Victor Segalen Bordeaux 2;
McHutchison JG, Poynard T. 1999 Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 19: 57- 65.Google Scholar
Morishima C, Gretch D. 1999 Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Clin Liver Dis. 3: 717- 740.Google Scholar
Oppenheimer E, Tobutt C, Taylor C,et al. 1994 Death and survival in a cohort of heroin addicts from London clinics: A 22-year follow-up study. Addiction. 89: 1299- 1308.Google Scholar
Perucci C, Davoli M, Rapiti E,et al. 1991 Mortality of intravenous drug users in Rome: A cohort study. Am J Public Health. 81: 1307- 1310.Google Scholar
Poynard T, MarcellinP, Lee S,et al. 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352: 1426- 1432.Google Scholar
Reichard O, Norkrans G, Fryden A,et al. 1998 Randomised double-blind placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 351: 83- 87.Google Scholar
Roth W, Marijke W, Erhard S. 1999 Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank. Lancet. 29: 1596- 1601.Google Scholar
Rotily M, Loubière S, Nixon J,et al. 1997 Analyse socio-économique de différentes stratégies de dépistage de l'hépatite chronique C dans la population française. Gastroenterol Clin Biol. 20: S33- S40.Google Scholar
Rotily M, Vernay-Vaisse C, Rousseau S,et al. 1999 Prevalence of HCV and HIV antibodies and related risk factors among entrants to the main south-eastern French prison. Clin Microbiol Infect. 5: 733- 739.Google Scholar
Russell L. 1986 Is prevention is better than cure? Washington: The Brookings Institution;
Seeff L. 1999 Natural history of hepatitis C. Am J Med. 107: 10S- 15S.Google Scholar
Shapiro S, Gershtein V, Elias N,et al. 1998 mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: Effects of interferon-alpha (IFN-alpha) treatment. Clin Exp Immunol. 114: 55- 60.Google Scholar
Sicard D. 2000 The precaution principle and blood transfusion. Transfus Clin Biol. 7: 220- 227.Google Scholar
Sonnenberg F, Beck J. 1993 Markov models in medical decision making: A practical guide. Med Decis Making. 13: 322- 338.Google Scholar
Tengs O, Adams M, Pliskin J,et al. 1995 Five hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15: 369- 390.Google Scholar
Tine F, Magrin S, Craxi A,et al. 1991 Interferon for chronic non-A, non-B hepatitis: A meta-analysis of randomized clinical trials. J Hepatol. 13: 192- 199.Google Scholar
Warnock M. 1994 Some moral problems in medicine. Health Econ. 3: 297- 300.Google Scholar
Wong J, Bennett W, Koff R,et al. 1998 Pre-treatment evaluation of chronic hepatitis C: Risks, benefits and costs. JAMA. 280: 2088- 2093.Google Scholar
Wong JB, Poynard T, Ling MH,et al. 2000 Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 95: 1524- 1530.Google Scholar
Woody G, Metzger D. 1993 Causes of death in injection-drug users. N Engl J Med. 329: 1661.Google Scholar